New drug combo shows promise for tough lung cancer
NCT ID NCT06812260
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times
Summary
This study tests a new immunotherapy drug (HLX10) combined with standard chemotherapy in 26 Japanese patients with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if the combination shrinks tumors and improves survival. Researchers will also monitor side effects and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kansai Medical University Hospital Department of Respiratory Oncology
Hirakata, Osaka, Japan
Conditions
Explore the condition pages connected to this study.